The growing shift towards patient-centric care
It’s been a trend for some time, but by embracing these new technologies, Pharma brands are shifting to a patient-centric model in ways that were inconceivable only a few years ago.
Patient’s expectations are changing.
Patients demand personalised, transparent, and timely care. The pharmaceutical industry, traditionally reliant on broad solutions, is moving toward more individualised approaches supported by AI and data analytics.
These technologies enable companies to tailor treatments to individual patient needs, monitor health in real-time, and ensure adherence to prescribed regimens.
With these supporting elements in mind, here are three ways the digital and AI-driven revolution is shifting healthcare to a greater patient-centricity.
Personalised healthcare
It’s not just a revolution. Digital tools like wearables and AI are evolving patient experience in almost every facet of the care chain. Evolution is co-occurring for patients, healthcare providers (HCPs), and pharma brands, increasing personalisation.
Pharma: for pharmaceutical companies, enhanced drug discovery by AI enables personalised medicine development. UK-based BenevolentAI has made notable strides in these areas. Through partnerships with AstraZeneca and Novartis, BenevolentAI leverages AI to identify precise drug targets and improve patient outcomes, especially in challenging conditions such as inflammatory bowel disease and liver disease.
Healthcare providers: When personalisation and engagement tools for patients are layered on top, today’s HCPs can provide better-tailored, more accurate, and timely patient care.
Patients: AI-driven tools allow patients to track their treatment, communicate with healthcare professionals, and receive real-time medication reminders, ensuring they stay on track with their healthcare plans.
Improving collaboration
Patients and HCPs alike need more connectivity and meaningful data. UCB has embraced digital transformation by improving how HCPs collaborate and engage with each other.
The UCB Impact Aid app is a digital tool designed to streamline communication and share real-time insights among HCPs, particularly during industry events and medical congresses. The net effect: UCB has enhanced knowledge exchange and strengthened relationships within the medical community, ensuring HCPs have the information and resources to make informed, patient-focused decisions.
Streamlining operations
While patient-centric care is at the forefront, the impact of digital transformation on pharmaceutical operations is equally profound. We’re seeing a trend emerging: as technology streamlines mental “manual muscle” tasks (operational efficiency), it’s freeing healthcare professionals to spend more time on assignments or tasks that require higher emotional—and intellectual—intelligence, such as diagnosis and connecting and engaging with patients at a deeper level.
AI and machine learning are revolutionising R&D processes, reducing the time it takes to develop new treatments and optimise clinical trials. Digital tools are streamlining everything from drug manufacturing to supply chain management, making the operation more agile and cost-effective.
Pfizer’s use of AI during the development of PAXLOVID, an oral treatment for COVID-19, shows how digital innovation accelerates operations. AI reduced critical supply chain steps by 67%, enabling Pfizer to produce 20,000 additional doses per batch. This application of AI sped up the drug’s production and ensured that patients received life-saving treatments faster, illustrating the significant impact of digital transformation on operational efficiency.
Sanofi’s AI platform, plai, aggregates real-time data across its operations, helping teams make faster and more informed decisions. With AI-driven tools, Sanofi has slashed research times, improving target identification by up to 30%. This accelerates drug discovery and ensures that more effective treatments reach patients sooner.
According to Sanofi, it’s not just research and drug discovery that’s enhanced. plai boosts productivity “across the value chain: from research to clinical operations to manufacturing and supply to business analysis.”
A healthy approach
Patient-centric care is transforming digitally in virtually every area of the value chain. The three fundamental shifts—personalised healthcare, improved collaboration, and operational streamlining—create new opportunities for pharmaceutical brands to improve patient care.
Personalisation allows treatments tailored to individual patient needs, moving beyond one-size-fits-all approaches. Collaborative digital platforms are breaking down traditional barriers, enabling healthcare providers to share insights and make more informed decisions. Meanwhile, operational innovations free medical professionals from routine tasks, allowing them to focus on what matters most: patient care and complex medical challenges.
The future of healthcare is here, and it is increasingly personalised, connected, and intelligent.
Transform with an experienced partner.
JOURNEY’s team brings over 25 years of global experience working with pharmaceutical and medical device companies, from driving transformative change in Europe to impactful projects across North America and the Middle East.
If these are areas of concern for you, we have the expertise and experience to help. Please reach out to us—together, we can make meaningful improvements to patients’ lives.
The growing shift towards patient-centric care
It’s been a trend for some time, but by embracing these new technologies, Pharma brands are shifting to a patient-centric model in ways that were inconceivable only a few years ago.
Patient’s expectations are changing.
Patients demand personalised, transparent, and timely care. The pharmaceutical industry, traditionally reliant on broad solutions, is moving toward more individualised approaches supported by AI and data analytics.
These technologies enable companies to tailor treatments to individual patient needs, monitor health in real-time, and ensure adherence to prescribed regimens.
With these supporting elements in mind, here are three ways the digital and AI-driven revolution is shifting healthcare to a greater patient-centricity.
Personalised healthcare
It’s not just a revolution. Digital tools like wearables and AI are evolving patient experience in almost every facet of the care chain. Evolution is co-occurring for patients, healthcare providers (HCPs), and pharma brands, increasing personalisation.
Pharma: for pharmaceutical companies, enhanced drug discovery by AI enables personalised medicine development. UK-based BenevolentAI has made notable strides in these areas. Through partnerships with AstraZeneca and Novartis, BenevolentAI leverages AI to identify precise drug targets and improve patient outcomes, especially in challenging conditions such as inflammatory bowel disease and liver disease.
Healthcare providers: When personalisation and engagement tools for patients are layered on top, today’s HCPs can provide better-tailored, more accurate, and timely patient care.
Patients: AI-driven tools allow patients to track their treatment, communicate with healthcare professionals, and receive real-time medication reminders, ensuring they stay on track with their healthcare plans.
Improving collaboration
Patients and HCPs alike need more connectivity and meaningful data. UCB has embraced digital transformation by improving how HCPs collaborate and engage with each other.
The UCB Impact Aid app is a digital tool designed to streamline communication and share real-time insights among HCPs, particularly during industry events and medical congresses. The net effect: UCB has enhanced knowledge exchange and strengthened relationships within the medical community, ensuring HCPs have the information and resources to make informed, patient-focused decisions.
Streamlining operations
While patient-centric care is at the forefront, the impact of digital transformation on pharmaceutical operations is equally profound. We’re seeing a trend emerging: as technology streamlines mental “manual muscle” tasks (operational efficiency), it’s freeing healthcare professionals to spend more time on assignments or tasks that require higher emotional—and intellectual—intelligence, such as diagnosis and connecting and engaging with patients at a deeper level.
AI and machine learning are revolutionising R&D processes, reducing the time it takes to develop new treatments and optimise clinical trials. Digital tools are streamlining everything from drug manufacturing to supply chain management, making the operation more agile and cost-effective.
Pfizer’s use of AI during the development of PAXLOVID, an oral treatment for COVID-19, shows how digital innovation accelerates operations. AI reduced critical supply chain steps by 67%, enabling Pfizer to produce 20,000 additional doses per batch. This application of AI sped up the drug’s production and ensured that patients received life-saving treatments faster, illustrating the significant impact of digital transformation on operational efficiency.
Sanofi’s AI platform, plai, aggregates real-time data across its operations, helping teams make faster and more informed decisions. With AI-driven tools, Sanofi has slashed research times, improving target identification by up to 30%. This accelerates drug discovery and ensures that more effective treatments reach patients sooner.
According to Sanofi, it’s not just research and drug discovery that’s enhanced. plai boosts productivity “across the value chain: from research to clinical operations to manufacturing and supply to business analysis.”
A healthy approach
Patient-centric care is transforming digitally in virtually every area of the value chain. The three fundamental shifts—personalised healthcare, improved collaboration, and operational streamlining—create new opportunities for pharmaceutical brands to improve patient care.
Personalisation allows treatments tailored to individual patient needs, moving beyond one-size-fits-all approaches. Collaborative digital platforms are breaking down traditional barriers, enabling healthcare providers to share insights and make more informed decisions. Meanwhile, operational innovations free medical professionals from routine tasks, allowing them to focus on what matters most: patient care and complex medical challenges.
The future of healthcare is here, and it is increasingly personalised, connected, and intelligent.
Transform with an experienced partner.
JOURNEY’s team brings over 25 years of global experience working with pharmaceutical and medical device companies, from driving transformative change in Europe to impactful projects across North America and the Middle East.
If these are areas of concern for you, we have the expertise and experience to help. Please reach out to us—together, we can make meaningful improvements to patients’ lives.
The growing shift towards patient-centric care
It’s been a trend for some time, but by embracing these new technologies, Pharma brands are shifting to a patient-centric model in ways that were inconceivable only a few years ago.
Patient’s expectations are changing.
Patients demand personalised, transparent, and timely care. The pharmaceutical industry, traditionally reliant on broad solutions, is moving toward more individualised approaches supported by AI and data analytics.
These technologies enable companies to tailor treatments to individual patient needs, monitor health in real-time, and ensure adherence to prescribed regimens.
With these supporting elements in mind, here are three ways the digital and AI-driven revolution is shifting healthcare to a greater patient-centricity.
Personalised healthcare
It’s not just a revolution. Digital tools like wearables and AI are evolving patient experience in almost every facet of the care chain. Evolution is co-occurring for patients, healthcare providers (HCPs), and pharma brands, increasing personalisation.
Pharma: for pharmaceutical companies, enhanced drug discovery by AI enables personalised medicine development. UK-based BenevolentAI has made notable strides in these areas. Through partnerships with AstraZeneca and Novartis, BenevolentAI leverages AI to identify precise drug targets and improve patient outcomes, especially in challenging conditions such as inflammatory bowel disease and liver disease.
Healthcare providers: When personalisation and engagement tools for patients are layered on top, today’s HCPs can provide better-tailored, more accurate, and timely patient care.
Patients: AI-driven tools allow patients to track their treatment, communicate with healthcare professionals, and receive real-time medication reminders, ensuring they stay on track with their healthcare plans.
Improving collaboration
Patients and HCPs alike need more connectivity and meaningful data. UCB has embraced digital transformation by improving how HCPs collaborate and engage with each other.
The UCB Impact Aid app is a digital tool designed to streamline communication and share real-time insights among HCPs, particularly during industry events and medical congresses. The net effect: UCB has enhanced knowledge exchange and strengthened relationships within the medical community, ensuring HCPs have the information and resources to make informed, patient-focused decisions.
Streamlining operations
While patient-centric care is at the forefront, the impact of digital transformation on pharmaceutical operations is equally profound. We’re seeing a trend emerging: as technology streamlines mental “manual muscle” tasks (operational efficiency), it’s freeing healthcare professionals to spend more time on assignments or tasks that require higher emotional—and intellectual—intelligence, such as diagnosis and connecting and engaging with patients at a deeper level.
AI and machine learning are revolutionising R&D processes, reducing the time it takes to develop new treatments and optimise clinical trials. Digital tools are streamlining everything from drug manufacturing to supply chain management, making the operation more agile and cost-effective.
Pfizer’s use of AI during the development of PAXLOVID, an oral treatment for COVID-19, shows how digital innovation accelerates operations. AI reduced critical supply chain steps by 67%, enabling Pfizer to produce 20,000 additional doses per batch. This application of AI sped up the drug’s production and ensured that patients received life-saving treatments faster, illustrating the significant impact of digital transformation on operational efficiency.
Sanofi’s AI platform, plai, aggregates real-time data across its operations, helping teams make faster and more informed decisions. With AI-driven tools, Sanofi has slashed research times, improving target identification by up to 30%. This accelerates drug discovery and ensures that more effective treatments reach patients sooner.
According to Sanofi, it’s not just research and drug discovery that’s enhanced. plai boosts productivity “across the value chain: from research to clinical operations to manufacturing and supply to business analysis.”
A healthy approach
Patient-centric care is transforming digitally in virtually every area of the value chain. The three fundamental shifts—personalised healthcare, improved collaboration, and operational streamlining—create new opportunities for pharmaceutical brands to improve patient care.
Personalisation allows treatments tailored to individual patient needs, moving beyond one-size-fits-all approaches. Collaborative digital platforms are breaking down traditional barriers, enabling healthcare providers to share insights and make more informed decisions. Meanwhile, operational innovations free medical professionals from routine tasks, allowing them to focus on what matters most: patient care and complex medical challenges.
The future of healthcare is here, and it is increasingly personalised, connected, and intelligent.
Transform with an experienced partner.
JOURNEY’s team brings over 25 years of global experience working with pharmaceutical and medical device companies, from driving transformative change in Europe to impactful projects across North America and the Middle East.
If these are areas of concern for you, we have the expertise and experience to help. Please reach out to us—together, we can make meaningful improvements to patients’ lives.
